Prognostic Implications of the Peripheral PLR and NLR in Predicting pCR after NACT in Breast Cancer Patients

Xiaoyan Jin,Ke Wang,Xuan Shao,Jian Huang
DOI: https://doi.org/10.21203/rs.3.rs-648889/v1
2021-01-01
Abstract:Abstract Background: Inflammatory response is extremely important in tumor progression, and it is very difficult to identify prognostic indicators for neoadjuvant therapy in breast cancer patients. The aim of this study was to mine the potential prognostic significance of the platelet-to-lymphocyte ratio (PLR) and neutrophil-to-lymphocyte ratio (NLR) in breast cancer patients receiving anthracycline- or taxane-based neoadjuvant chemotherapy (NACT).Methods: Sixty-seven women diagnosed with breast cancer who received neoadjuvant therapy were enrolled in the study and then underwent surgeries. Before starting NACT, the PLR and NLR were calculated. The optimal cutoff value was calculated using receiver operating characteristic curve analyses, and the ROC curve analysis indicated that 106.3 and 2.464 were the best cutoff values for the PLR and NLR, respectively. The optimal cutoff values for the NLR and PLR were used to divide patients into low and high NLR groups and low and high PLR groups. Independent prognostic biomarkers and value the of PLR and NLR were assessed with univariate and multivariate logistic regression models. The connection between the NLR/PLR and pathological complete response (pCR), together with other clinical/pathological factors, was evaluated by Fisher's exact test or Pearson's x2 as appropriate.Results: Logistic regression model analyses revealed that patients with a high PLR correlated remarkably with better pCR than those with a low PLR. The results indicated that by using the cutoff value of 106.3, PLR had prognostic significance. However, there was no significant difference in NLR if analyzed separately. However, by combining PLR and NLR, the NLRhigh and PLRhigh subgroups achieved a significantly higher rate of pCR than the NLRIow/PLRIow subgroup (OR 0.153, 95% CI 0.068-0.876, p=0.008). Therefore, the combination of NLRhigh/PLRhigh was an independent prognostic factor different from common factors, such as PLR, Ki-67, and chemotherapy regimen.Conclusions: The PLR may serve as a potential marker of the efficacy of neoadjuvant therapy in breast cancer, enabling oncologists to intervene earlier. Peripheral blood NLR and PLR can reflect the immune status of patients. High levels of both of them may indicate immune activation status and predict the pCR rate of NACT treatment in breast cancer patients.
What problem does this paper attempt to address?